Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 9Other hematologic neoplasm 5Sarcoma 3CNS 2Tumor-Agnostic 1Myeloid 1Lymphoid 1Head & Neck 1Dermatologic 1

Conditions

Neuroblastoma 2Recurrence 1

Interventions

Magnetic Resonance Spectroscopy 73Temozolomide 68Specimen Handling 48Radiotherapy 40Radiosurgery 29Bevacizumab 26Radiation 25Cyclophosphamide 25Nivolumab 21Biopsy 21pembrolizumab 20Carboplatin 16X-Rays 14Lomustine 13Ipilimumab 13fludarabine 12Irinotecan 12Vincristine 11Topotecan 11Surgical Procedures, Operative 11Cisplatin 11Blood Specimen Collection 11trametinib 9dinutuximab 9Immunoglobulin G 8Etoposide 8Doxorubicin 8lutetium Lu 177 dotatate 7fludarabine phosphate 7atezolizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sorafenib × CNS × 90 days × Clear all
NCT02559778 2026-04-28

PEDS-PLAN

Milton S. Hershey Medical Center

Phase 2 Recruiting
500 enrolled
CNS

Neuroblastoma

NCT02298348 2026-03-23

N2013-02

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Active not recruiting
18 enrolled
CNS

Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡